- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02823366
Fenofibrate for Patients With Primary Biliary Cirrhosis Who Had An Inadequate Response to Ursodeoxycholic Acid
September 27, 2022 updated by: Han Ying, Xijing Hospital of Digestive Diseases
Ursodeoxycholic acid (UDCA) has been the only treatment for PBC approved by US and European drug administrations.
Long-term use of UDCA(13-15 mg/kg/day) in patients with PBC improves serum liver biochemistries and survival free of liver transplantation However, about 40% of patients do not respond to UDCA optimally as assessed by known criteria for biochemical response.
Those patients represent the group in need for additional therapies, having increased risk of disease progression and decreased survival free of liver transplantation.
Both lab research and some clinical studies suggest that fenofibrate could improve cholestasis in multiple ways including reduce of bile acid synthesis, increase of biliary secretion and anti-inflammation effect.
Here we start a random, open and parallel clinical research to explore the effect of fenofibrate in the PBC treatment.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
104
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ying Han, Ph.D
- Phone Number: 86-29-84771539
- Email: hanying@fmmu.edu.cn
Study Contact Backup
- Name: Yongquan Shi, Ph.D
- Phone Number: 86-29-84771515
- Email: shiyquan@fmmu.edu.cn
Study Locations
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710032
- Recruiting
- Xijing Hosipital
-
Contact:
- Ying Han, Ph.D
- Phone Number: 86-29-84771539
- Email: hanying@fmmu.edu.cn
-
Contact:
- Yongquan Shi, Ph.D
- Phone Number: 86-29-84771515
- Email: shiyquan@fmmu.edu.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Signed informed consent
- Patient with PBC defined by 2 in 3 of the following criteria: a.Positive antimitochondrial antibody type M2; b.Abnormal serum alkaline phosphatases (ALP > 1,5N) and aminotransferase (AST or ALT > 1N) activities; c.Histological hepatic injuries consistent with PBC.
- Had been treated with UDCA more than 6 months, and failed to achieve a complete biochemical response.
Exclusion Criteria:
- Pregnancy or desire of pregnancy.
- Breast-feeding.
- Co-existing liver diseases such as acute or chronic viral hepatitis, alcoholic liver disease, choledocholithiasis, autoimmune hepatitis, biopsy-proven non-alcoholic fatty liver disease, Wilson's disease and hemochromatosis.
- History or presence of hepatic decompensation (e.g., variceal bleeds, encephalopathy, or poorly controlled ascites).
- History of urolithiasis, nephritis or renal failure (clearance of creatinine < 60 ml/mn).
- Hepatotoxic drugs use before recruiting.
- Fenofibrate anaphylaxis.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Fenofibrate + UDCA
Fenofibrate in combination with ursodeoxycholic acid
|
|
Active Comparator: Monotherapy
UDCA alone
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of patients with complete biochemical response
Time Frame: Week 24
|
Normalization of alkaline phosphatase (ALP) or decrease of ALP by more than 40% compared to the baseline.
|
Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in liver stiffness status measured by magnetic resonance elastography.
Time Frame: Week 48
|
The change of liver stiffness status at the end of the study compared to baseline checked by magnetic resonance elastography.
|
Week 48
|
Change in liver biopsy examinations according to conventional Ludwig system.
Time Frame: Week 48
|
Histological evolution will be checked by liver biopsy at the end of the study to compare with baseline histological status.
The Ludwig histological classification schemes will be used, which categorised the disease into four stages.
|
Week 48
|
Change in serum levels of ALP compared to the baseline.
Time Frame: Weeks 0, 4, 8, 12, 24, and 48
|
Absolute change in serum levels of ALP compared to the baseline.
|
Weeks 0, 4, 8, 12, 24, and 48
|
Change in serum levels of bilirubin compared to the baseline.
Time Frame: Weeks 0, 4, 8, 12, 24, and 48
|
Absolute change in serum levels of bilirubin compared to the baseline.
|
Weeks 0, 4, 8, 12, 24, and 48
|
Change in serum levels of transaminase compared to the baseline.
Time Frame: Weeks 0, 4, 8, 12, 24, and 48
|
Absolute change in serum levels of transaminase compared to the baseline.
|
Weeks 0, 4, 8, 12, 24, and 48
|
Change in GLOBE risk scores after treatment.
Time Frame: Week 48
|
The prognostic scores will be calculated at entry and end of study by GLOBE scoring system, which calculated based on serum values of bilirubin, ALP, albumin and platelet count after 1 year of treatment and age at baseline.
|
Week 48
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in symptom-pruritus.
Time Frame: Week 24
|
The symptom of pruritus will be evaluated by questionnaire before enrolment and at the end of the study.
|
Week 24
|
Change in symptom-fatigue.
Time Frame: Week 24
|
The symptom of fatigue will be evaluated by Fatigue Impact Scale before enrolment and at the end of the study.
|
Week 24
|
Change in serum Immunoglobulin M Levels.
Time Frame: Week 24
|
Absolute change in serum levels of Immunoglobulin M compared to the baseline.
|
Week 24
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2016
Primary Completion (Anticipated)
December 1, 2023
Study Completion (Anticipated)
December 1, 2023
Study Registration Dates
First Submitted
January 28, 2016
First Submitted That Met QC Criteria
June 30, 2016
First Posted (Estimate)
July 6, 2016
Study Record Updates
Last Update Posted (Actual)
September 30, 2022
Last Update Submitted That Met QC Criteria
September 27, 2022
Last Verified
June 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Liver Diseases
- Biliary Tract Diseases
- Bile Duct Diseases
- Cholestasis, Intrahepatic
- Cholestasis
- Fibrosis
- Liver Cirrhosis
- Liver Cirrhosis, Biliary
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites
- Hypolipidemic Agents
- Lipid Regulating Agents
- Fenofibrate
Other Study ID Numbers
- KY20151230-5
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Biliary Cirrhosis
-
University Health Network, TorontoUnknown
-
CymaBay Therapeutics, Inc.TerminatedPrimary Biliary Cirrhosis (PBC)Germany, United States, Canada, United Kingdom, Poland
-
Xijing Hospital of Digestive DiseasesUnknownPrimary Biliary CirrhosisChina
-
University of AarhusAarhus University Hospital; Hvidovre University HospitalRecruiting
-
CymaBay Therapeutics, Inc.RecruitingPrimary Biliary CirrhosisUnited States, Korea, Republic of, Belgium, Spain, France, Switzerland, Romania, United Kingdom, Austria, Israel, Australia, Argentina, Canada, Chile, Germany, Greece, Hungary, Italy, Mexico, Netherlands, Poland, Czechia, New Zealand, Turke... and more
-
Target PharmaSolutions, Inc.Active, not recruitingBiliary Cirrhosis, PrimaryUnited States
-
IpsenActive, not recruitingPrimary Biliary CirrhosisUnited States, France, Spain, Belgium, Germany, Switzerland, Brazil, United Kingdom, Argentina, Canada, Chile, Italy, South Africa, Turkey
-
Instituto Mexicano del Seguro SocialActive, not recruitingPrimary Biliary CirrhosisMexico
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingPrimary Biliary CirrhosisChina
-
Zydus Therapeutics Inc.CompletedPrimary Biliary CirrhosisUnited States
Clinical Trials on UDCA
-
Dr. Falk Pharma GmbHCompleted
-
Nanjing Chia-tai Tianqing PharmaceuticalRecruitingPrimary Biliary CholangitisChina
-
Daewoong Pharmaceutical Co. LTD.Completed
-
Sheffield Teaching Hospitals NHS Foundation TrustJP Moulton Charitable Foundation; PRO.MED.CS Praha a.s.; Clinical Trials Research...CompletedParkinson's DiseaseUnited Kingdom
-
Fuzhou General HospitalActive, not recruitingPrimary Sclerosing Cholangitis
-
Xijing Hospital of Digestive DiseasesUnknownPrimary Biliary CirrhosisChina
-
Xijing Hospital of Digestive DiseasesUnknownPrimary Biliary CirrhosisChina
-
University of TennesseeUniversity of Colorado, Denver; Baylor College of Medicine; Children's Hospital... and other collaboratorsCompletedPrimary Sclerosing CholangitisUnited States
-
Daewoong Pharmaceutical Co. LTD.RecruitingGastric CancerKorea, Republic of
-
MinaPharm PharmaceuticalsRecruiting